Article

Sleep Quality and Preclinical Alzheimer Disease

JAMA neurology 03/2013; 70(5):1-7. DOI: 10.1001/jamaneurol.2013.2334
Source: PubMed

ABSTRACT

IMPORTANCE Sleep and circadian problems are very common in Alzheimer disease (AD). Recent animal studies suggest a bidirectional relationship between sleep and β-amyloid (Aβ), a key molecule involved in AD pathogenesis. OBJECTIVE To test whether Aβ deposition in preclinical AD, prior to the appearance of cognitive impairment, is associated with changes in quality or quantity of sleep. DESIGN Cross-sectional study conducted from October 2010 to June 2012. SETTING General community volunteers at the Washington University Knight Alzheimer's Disease Research Center. PARTICIPANTS Cognitively normal individuals (n = 145) 45 years and older were recruited from longitudinal studies of memory and aging at the Washington University Knight Alzheimer's Disease Research Center. Valid actigraphy data were recorded in 142. The majority (124 of 142) were recruited from the Adult Children Study, in which all were aged 45 to 75 years at baseline and 50% have a parental history of late-onset AD. The rest were recruited from a community volunteer cohort in which all were older than 60 years and healthy at baseline. MAIN OUTCOME MEASURES Sleep was objectively measured using actigraphy for 2 weeks. Sleep efficiency, which is the percentage of time in bed spent asleep, was the primary measure of sleep quality. Total sleep time was the primary measure of sleep quantity. Cerebrospinal fluid Aβ42 levels were used to determine whether amyloid deposition was present or absent. Concurrent sleep diaries provided nap information. RESULTS Amyloid deposition, as assessed by Aβ42 levels, was present in 32 participants (22.5%). This group had worse sleep quality, as measured by sleep efficiency (80.4% vs 83.7%), compared with those without amyloid deposition, after correction for age, sex, and APOE ϵ4 allele carrier status (P = .04). In contrast, quantity of sleep was not significantly different between groups, as measured by total sleep time. Frequent napping, 3 or more days per week, was associated with amyloid deposition (31.2% vs 14.7%; P = .03). CONCLUSIONS AND RELEVANCE Amyloid deposition in the preclinical stage of AD appears to be associated with worse sleep quality but not with changes in sleep quantity.

Download full-text

Full-text

Available from: David M Holtzman, Jul 14, 2014
  • Source
    • "De récentes études observationnelles ont permis de confirmer les relations existant entre les troubles de sommeil et la maladie d'Alzheimer. Ju et al. (2013) ont montré que, chez des sujets âgés de 45 à 75 ans, les taux de peptide Aß dans le liquide céphalorachidien (indiquant la présence de plaques amyloïdes) étaient corrélés positivement à l'efficacité de sommeil et négativement à la durée des éveils nocturnes (ces variables étant estimées par actimétrie). Spira et al. (2013) rapportent que la durée de sommeil, estimée par auto-questionnaire, est corrélée négativement aux dépôts amyloïdes, notamment au niveau du précunéus, région précocement atteinte dans la maladie d'Alzheimer). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Le sommeil est un moment privilégié favorisant la consolidation des souvenirs en mémoire à long terme. Les travaux menés au cours des dernières années ont permis de préciser les substrats neurobiologiques sous-tendant cet effet bénéfique du sommeil sur la mémoire et ont abouti à la proposition de deux modèles : l’hypothèse du dialogue hippocampo-néocortical et la théorie de l’homéostasie synaptique (ou recalibrage synaptique). Le vieillissement et, de manière plus marquée la maladie d’Alzheimer, s’accompagnent de troubles du sommeil qui semblent participer aux troubles de la consolidation mnésique. Dans cet article, nous proposons une synthèse des études portant sur les liens entre sommeil et mémoire, et sur la façon dont ces liens sont modifiés pendant le vieillissement normal et pathologique.
    Full-text · Article · Dec 2015 · Biologie Aujourd'hui
  • Source
    • "Recent studies show sleep disorder is strongly correlated with cognitive impairment [20], and even the chance of getting AD [24]. Our efficacy evaluation included determination of body magnesium status, tests of cognition in four domains (executive function, working memory, attention , and episodic memory), and measurements of sleep quality and emotional state [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Cognitive impairment is a major problem in elderly, affecting quality of life. Pre-clinical studies show that MMFS-01, a synapse density enhancer, is effective at reversing cognitive decline in aging rodents. Objective: Since brain atrophy during aging is strongly associated with both cognitive decline and sleep disorder, we evaluated the efficacy of MMFS-01 in its ability to reverse cognitive impairment and improve sleep. Methods: We conducted a randomized, double-blind, placebo-controlled, parallel-designed trial in elderly subjects (age 50-70) with cognitive impairment. Subjects were treated with MMFS-01 (n = 23) or placebo (n = 21) for 12 weeks and cognitive ability, sleep quality, and emotion were evaluated. Overall cognitive ability was determined by a composite score of tests in four major cognitive domains. Results: With MMFS-01 treatment, overall cognitive ability improved significantly relative to placebo (p = 0.003; Cohen's d = 0.91). Cognitive fluctuation was also reduced. The study population had more severe executive function deficits than age-matched controls from normative data and MMFS-01 treatment nearly restored their impaired executive function, demonstrating that MMFS-01 may be clinically significant. Due to the strong placebo effects on sleep and anxiety, the effects of MMFS-01 on sleep and anxiety could not be determined. Conclusions: The current study demonstrates the potential of MMFS-01 for treating cognitive impairment in elderly.
    Preview · Article · Oct 2015 · Journal of Alzheimer's disease: JAD
  • Source
    • "d Abnormal circadian locomotor and core-body temperature rhythms d Suprachiasmatic d Vasopressin d Neurotensin d VIP Harper et al., 2001, 2008; Hu et al., 2013; van Someren et al., 1996 Sleep d Fragmented sleep pattern and reduced sleep time d EEG changes d Intermediate nucleus (ventrolateral preoptic area) d Lateral area d Galanin d Orexin d MCH Ju et al., 2013; Liguori et al., 2014; Lim et al., 2014; Prinz et al., 1982; Schmidt et al., 2013 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning decades prior to the cognitive decline. While cognitive deficits remain the cardinal manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well as into new opportunities for therapeutic interventions and biomarker development.
    Full-text · Article · Sep 2015 · Cell metabolism
Show more